

Product Data Sheet

Product Name: Brilaroxazine

Cat. No.: GC64676

Chemical Properties

Cas. No. 1239729-06-6


Formula $C_{22}H_{25}Cl_2N_3O_3$ M.Wt 450.36

Solubility DMSO : 100 mg/mL (222.04 mM; Storage 4°C, protect from light
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D₂, D₃, and D₄ receptors, 5-HT_{1A} (K_i=1.5 nM) and 5-HT_{2A} (K_i=2.5 nM), and has antagonist activity at 5-HT_{2B} (K_i=0.19 nM), and 5-HT₇ (K_i=2.7 nM) receptors[1]. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo[2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO₂, and pulmonary blood vessel structural changes[1].

[1]. Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits

[2]. Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. Eur J Pharmacol. 2018 May 15;827:159-166.

[3]. L. Bhat, et al. Rp5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension In Rats.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA